Aska Pharmaceutical researches and develops new medicine in R&D system with a balanced combination of cutting-edge pharmaceutical technology and a long experience, to grow and expand persistently as a medium R&D company focusing on a specialized field.
Using this system, we will improve our R&D pipelines by promoting early development in collaboration with both Japanese and foreign businesses as well as efficient use of resources by selecting and focusing on a field of development.
We promise further R&D activities to achieve a steady production of medicine that contributes to the future of medicine and people's health.
We have been producing new and highly innovative medicines.
Altat, a remedy for peptic ulcer and gastritis, that includes H2 blockers with a unique structure and Prostal, a treatment for prostatic hypertrophy and cancer, that uses steroid hormone technology are a result of our exceptional development abilities.
Also, Lipidil, a treatment for hyperlipidemia, has been successful in clinical fields all over the world and has received high regards.
In addition, we have made our marks in the field of thyroid diseases and gynecology due to our hormone medications such as Thyradin, a thyroid hormone drug; Ange, oral contraceptive agent; and Menoaid Combipatch, a climacteric syndrome treatment.
We also have actively been collaborating in developing with other Japanese and foreign companies to produce L-105, a hepatic encephalopathy treatment with rifaximin as an active ingredient; AKP-501, a fertility treatment with follicle stimulating hormone (FSH) preparation of recombinant DNA origin as an active agent; and CDB-2914, a uterine leiomyomata treatment with ulipristal acetate as an active ingredient.